Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leah R Hanson

Showing results (1-10 of 79) with videos related to

Pageof 8
Sort By:
Journal of Neuroimmune Pharmacology : the Official Journal of the Society on Neuroimmune Pharmacology|November 28, 2007
Strategies for intranasal delivery of therapeutics for the prevention and treatment of neuroAIDSLeah R Hanson, William H Frey
BMC Neuroscience|December 19, 2008
Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative diseaseLeah R Hanson, William H Frey
Neuroscience Letters|March 6, 2012
Intranasal delivery of siRNA to the olfactory bulbs of mice via the olfactory nerve pathwayDan B Renner, William H Frey, Leah R Hanson
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|January 4, 2020
Intranasal Insulin: a Treatment Strategy for AddictionBhavani Kashyap, Leah R Hanson, William H Frey Ii
The Journal of Pharmacology and Experimental Therapeutics|October 24, 2008
Novel vasoconstrictor formulation to enhance intranasal targeting of neuropeptide therapeutics to the central nervous systemShyeilla V Dhuria, Leah R Hanson, William H Frey
Molecular Pharmaceutics|April 28, 2010
Trigeminal pathways deliver a low molecular weight drug from the nose to the brain and orofacial structuresNeil J Johnson, Leah R Hanson, William H Frey
Journal of Pharmaceutical Sciences|November 26, 2008
Intranasal drug targeting of hypocretin-1 (orexin-A) to the central nervous systemShyeilla V Dhuria, Leah R Hanson, William H Frey
Journal of Pharmaceutical Sciences|October 31, 2009
Intranasal delivery to the central nervous system: mechanisms and experimental considerationsShyeilla V Dhuria, Leah R Hanson, William H Frey
Pharmaceuticals (Basel, Switzerland)|February 26, 2025
Brain Glucose Hypometabolism and Brain Iron Accumulation as Therapeutic Targets for Alzheimer's Disease and Other CNS DisordersIndira Y Rao, Leah R Hanson, William H Frey Ii
Pharmaceuticals (Basel, Switzerland)|January 30, 2021
Mechanisms of Intranasal Deferoxamine in Neurodegenerative and Neurovascular DiseaseJacob Kosyakovsky, Jared M Fine, William H Frey, et al.
Pageof 8

Showing results (1-10 of 79) with videos related to

Sort By:
Pageof 8
Journal of Neuroimmune Pharmacology : the Official Journal of the Society on Neuroimmune Pharmacology|November 28, 2007
Strategies for intranasal delivery of therapeutics for the prevention and treatment of neuroAIDSLeah R Hanson, William H Frey
BMC Neuroscience|December 19, 2008
Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative diseaseLeah R Hanson, William H Frey
Neuroscience Letters|March 6, 2012
Intranasal delivery of siRNA to the olfactory bulbs of mice via the olfactory nerve pathwayDan B Renner, William H Frey, Leah R Hanson
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|January 4, 2020
Intranasal Insulin: a Treatment Strategy for AddictionBhavani Kashyap, Leah R Hanson, William H Frey Ii
The Journal of Pharmacology and Experimental Therapeutics|October 24, 2008
Novel vasoconstrictor formulation to enhance intranasal targeting of neuropeptide therapeutics to the central nervous systemShyeilla V Dhuria, Leah R Hanson, William H Frey
Molecular Pharmaceutics|April 28, 2010
Trigeminal pathways deliver a low molecular weight drug from the nose to the brain and orofacial structuresNeil J Johnson, Leah R Hanson, William H Frey
Journal of Pharmaceutical Sciences|November 26, 2008
Intranasal drug targeting of hypocretin-1 (orexin-A) to the central nervous systemShyeilla V Dhuria, Leah R Hanson, William H Frey
Journal of Pharmaceutical Sciences|October 31, 2009
Intranasal delivery to the central nervous system: mechanisms and experimental considerationsShyeilla V Dhuria, Leah R Hanson, William H Frey
Pharmaceuticals (Basel, Switzerland)|February 26, 2025
Brain Glucose Hypometabolism and Brain Iron Accumulation as Therapeutic Targets for Alzheimer's Disease and Other CNS DisordersIndira Y Rao, Leah R Hanson, William H Frey Ii
Pharmaceuticals (Basel, Switzerland)|January 30, 2021
Mechanisms of Intranasal Deferoxamine in Neurodegenerative and Neurovascular DiseaseJacob Kosyakovsky, Jared M Fine, William H Frey, et al.
Pageof 8